Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employmen...
Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also p...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Dollar Tree, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 27 May 2025 in which we reassessed the appropriateness of the ratings in the context of t...
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has entered into a new credit facility providing for up to $500 million of term loans with its current partner Oxford Finance LLC (“Oxford”). The new credit facility will replace Vera’s existing $50 million...
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance ...
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p
Erasca to Present at Upcoming Investor Conferences in June SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences. Jefferies Global Healthcare Conference (June 3-5, 2025)Location: New York, NYFormat: Fireside ChatDate...
Upgrading Consumer Discretionary (XLY) to Overweight A weak 20-year note auction last Wednesday sparked the first semi-meaningful pullback since this lockout rally began on April 22nd, which is when we turned short-term bullish (4/22/25 Compass) as the SPX was testing 5100-5120 support. We will be watching the 10- and 30-year Treasury yields closely, as both are approaching important resistance levels (more on that below). Unsurprisingly, SPX only tested short-term gap support on the pullback a...
Erasca Reports First Quarter 2025 Business Updates and Financial Results Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developin...
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology co...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares of Class A common stock to eleven (11) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in ...
Erasca to Present at the Bank of America Securities Health Care Conference SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in one-on-one investor m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.